Our Compliance Program
Ardelyx has adopted a Code of Business Conduct and Ethics and has established a comprehensive Compliance Program to deliver on our commitment to integrity. Please view the Ardelyx Code of Conduct here. The key components of Ardelyx’s Compliance Program are described below, addressing each of the elements of an effective compliance program as outlined in the HHS OIG Compliance Program Guidance for Pharmaceutical Manufacturers (“OIG Guidance”), and include policies consistent with the PhRMA Code on Interactions with Healthcare Professionals (“PhRMA Code”). As the OIG Guidance envisions, we have designed our Compliance Program to fit the size, resources, market position, and other unique aspects of our Company. Ardelyx is committed to the regular review, assessment, and development of our Compliance Program and to address the evolving regulatory and business environment.
Ardelyx’s Compliance Program addresses among other things:
- Compliance leadership, responsibility, and oversight
- Policies and procedures
- Education and training
- Internal communication and reporting
- Auditing and monitoring
- Enforcement and discipline
- Corrective action procedures
Reporting Suspected Misconduct
Ardelyx maintains an “open door” environment in which employees, contractors, vendors, or other whistleblowers are comfortable speaking up and raising questions about conduct that they know, or suspect, may be inappropriate without fear of retaliation. You may report suspected misconduct to the Chief Compliance Officer directly or to any of the following:
- Your supervisor or another supervisor, if you are an Ardelyx employee or contractor
- The Chief Compliance Officer, the Chief Financial and Operations Officer, the Chief Legal and Administrative Officer, the Audit Committee Chair, and/or any business partner in Legal/Compliance or Human Resources
- Our Ethics helpline at: 1.877.441.1591, online through the Secure Web Form at www.openboard.info/ARDX, or via an email link through www.openboard.info/ARDX.
You may contact Ardelyx’s Chief Compliance Officer directly at compliance@ardelyx.com.
State of California Compliance Program Declaration here
Ardelyx Code of Conduct here
Product Disclosure Details
- Colorado HB 19-1131 & Connecticut HB 6669 IBS-C | Hyperphosphatemia
- Information for Vermont Prescribers of Prescription Drugs IBS-C | Hyperphosphatemia